Would an Innovative Medicines Initiative work in Japan?
This article was originally published in SRA
Speaking as the president of the European pharmaceutical industry federation EFPIA, Christopher Viehbacher is quite clear that change and innovation in all areas, ranging from R&D to regulatory approaches to new drugs themselves, are essential if healthcare systems are to prosper.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.